Literature DB >> 15800993

Hepatic gene expression profiles associated with fibrosis progression and hepatocarcinogenesis in hepatitis C patients.

Run-Xuan Shao1, Yujin Hoshida, Motoyuki Otsuka, Naoya Kato, Ryosuke Tateishi, Takuma Teratani, Shuichiro Shiina, Hiroyoshi Taniguchi, Masaru Moriyama, Takao Kawabe, Masao Omata.   

Abstract

AIM: To determine fibrosis progression and hepatocellular carcinoma (HCC), using simultaneous gene expression analysis.
METHODS: Total RNA samples were extracted from liver biopsies from 19 patients with hepatitis C virus (HCV) infection and 3 patients without HCV infection. Among the 19 HCV-infected patients, 7 and 12 patients had grade F1-2 and F3-4 fibrosis, respectively. Of the 12 patients with F3-4 fibrosis, 8 had HCC. Gene expression in the liver samples was determined using an oligonucleotide microarray. The following comparisons were performed: normal livers vs HCV-infected livers; F1-2 vs F3-4; and F3-4 with HCC vs F3-4 without HCC. Genes that were differentially expressed between these groups were identified based on signal-to-noise ratios.
RESULTS: In the HCV-infected livers, genes involved in immune responses were highly expressed. Expression levels of genes for plasma proteins and drug-metabolizing enzymes were decreased and those of genes involved in the cell cycle and oncogenesis were increased in the F3-4 cases as compared to the F1-2 cases. Among the F3-4 cases, genes involved in carbohydrate metabolism tended to be more highly expressed in patients with HCC than in patients without HCC.
CONCLUSION: We identified genes that are associated with fibrosis progression and hepatocarcinogenesis. This information may be used to detect increased carcinogenic potential in the livers of patients with HCV infection.

Entities:  

Mesh:

Year:  2005        PMID: 15800993      PMCID: PMC4305724          DOI: 10.3748/wjg.v11.i13.1995

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  13 in total

1.  Differential gene expression between chronic hepatitis B and C hepatic lesion.

Authors:  M Honda; S Kaneko; H Kawai; Y Shirota; K Kobayashi
Journal:  Gastroenterology       Date:  2001-03       Impact factor: 22.682

2.  Isolation and characterization of a novel human gene, VANGL1, as a therapeutic target for hepatocellular carcinoma.

Authors:  Ryuichiro Yagyu; Ryuji Hamamoto; Yoichi Furukawa; Hiroshi Okabe; Takehira Yamamura; Yusuke Nakamura
Journal:  Int J Oncol       Date:  2002-06       Impact factor: 5.650

3.  Identification of novel tumor markers in hepatitis C virus-associated hepatocellular carcinoma.

Authors:  Maria W Smith; Zhaoxia N Yue; Gary K Geiss; Natalya Y Sadovnikova; Victoria S Carter; Loreto Boix; Catherine A Lazaro; Gary B Rosenberg; Roger E Bumgarner; Nelson Fausto; Jordi Bruix; Michael G Katze
Journal:  Cancer Res       Date:  2003-02-15       Impact factor: 12.701

4.  cDNA microarray analysis of macroregenerative and dysplastic nodules in end-stage hepatitis C virus-induced cirrhosis.

Authors:  Robert A Anders; Lisa M Yerian; Maria Tretiakova; Jon M Davison; Richard J Quigg; Peter H Domer; Jamie Hoberg; John Hart
Journal:  Am J Pathol       Date:  2003-03       Impact factor: 4.307

5.  Interferon alfa regulated gene expression in patients initiating interferon treatment for chronic hepatitis C.

Authors:  Xuhuai Ji; Ramsey Cheung; Stewart Cooper; Qingqin Li; Harry B Greenberg; Xiao-Song He
Journal:  Hepatology       Date:  2003-03       Impact factor: 17.425

6.  Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression.

Authors:  H Okabe; S Satoh; T Kato; O Kitahara; R Yanagawa; Y Yamaoka; T Tsunoda; Y Furukawa; Y Nakamura
Journal:  Cancer Res       Date:  2001-03-01       Impact factor: 12.701

7.  Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients.

Authors:  S Takano; O Yokosuka; F Imazeki; M Tagawa; M Omata
Journal:  Hepatology       Date:  1995-03       Impact factor: 17.425

8.  UDP-glucuronosyltransferase 1A7 genetic polymorphisms are associated with hepatocellular carcinoma in japanese patients with hepatitis C virus infection.

Authors:  Yue Wang; Naoya Kato; Yujin Hoshida; Motoyuki Otsuka; Hiroyoshi Taniguchi; Masaru Moriyama; Shuichiro Shiina; Takao Kawabe; Yoichi M Ito; Masao Omata
Journal:  Clin Cancer Res       Date:  2004-04-01       Impact factor: 12.531

9.  Glypican-3 is overexpressed in human hepatocellular carcinoma.

Authors:  Young Kwan Sung; Sun Young Hwang; Mi Kyung Park; Mohammad Farooq; In Sook Han; Han Ik Bae; Jung-Chul Kim; Moonkyu Kim
Journal:  Cancer Sci       Date:  2003-03       Impact factor: 6.716

10.  Hepatitis C virus and liver disease: global transcriptional profiling and identification of potential markers.

Authors:  Maria W Smith; Zhaoxia N Yue; Marcus J Korth; Hao A Do; Loreto Boix; Nelson Fausto; Jordi Bruix; Robert L Carithers; Michael G Katze
Journal:  Hepatology       Date:  2003-12       Impact factor: 17.425

View more
  21 in total

Review 1.  Genetics of hepatocellular carcinoma.

Authors:  Andreas Teufel; Frank Staib; Stephan Kanzler; Arndt Weinmann; Henning Schulze-Bergkamen; Peter-R Galle
Journal:  World J Gastroenterol       Date:  2007-04-28       Impact factor: 5.742

2.  Novel serum markers of fibrosis progression for the follow-up of hepatitis C virus-infected patients.

Authors:  Frédérique Caillot; Martine Hiron; Odile Goria; Marie Gueudin; Arnaud Francois; Michel Scotte; Maryvonne Daveau; Jean-Philippe Salier
Journal:  Am J Pathol       Date:  2009-05-28       Impact factor: 4.307

Review 3.  Immunomodulatory effects of transforming growth factor-β in the liver.

Authors:  Hans-Theo Schon; Ralf Weiskirchen
Journal:  Hepatobiliary Surg Nutr       Date:  2014-12       Impact factor: 7.293

4.  Development of a hepatocellular carcinoma in a chronic hepatitis C patient 18 years after achieving a sustained virological response to interferon therapy: case report and literature review.

Authors:  Masaya Saito; Yasushi Seo; Yoshihiko Yano; Akira Miki; Yukiko Morinaga; Tomoo Itoh; Masaru Yoshida; Takeshi Azuma
Journal:  Clin J Gastroenterol       Date:  2012-02-18

5.  Gene profiling of early and advanced liver disease in chronic hepatitis C patients.

Authors:  Saira Sarfraz Khalid; Saeed Hamid; Anwar A Siddiqui; Asaf Qureshi; Nilofer Qureshi
Journal:  Hepatol Int       Date:  2011-01-22       Impact factor: 6.047

6.  A novel microRNA boosts hyper-β-oxidation of fatty acids in liver by impeding CEP350-mediated sequestration of PPARα and thus restricts chronic hepatitis C.

Authors:  Suchandrima Ghosh; Joyeeta Chakraborty; Avijit Goswami; Sayantani Bhowmik; Susree Roy; Amit Ghosh; Sakshi Dokania; Priyanka Kumari; Simanti Datta; Abhijit Chowdhury; Suvendra Nath Bhattacharyya; Raghunath Chatterjee; Soma Banerjee
Journal:  RNA Biol       Date:  2020-06-07       Impact factor: 4.652

7.  Hematogenous macrophage depletion reduces the fibrotic scar and increases axonal growth after spinal cord injury.

Authors:  Y Zhu; C Soderblom; V Krishnan; J Ashbaugh; J R Bethea; J K Lee
Journal:  Neurobiol Dis       Date:  2014-11-04       Impact factor: 5.996

8.  Tumor necrosis factor-alpha 308.2 polymorphism is associated with advanced hepatic fibrosis and higher risk for hepatocellular carcinoma.

Authors:  Jen-Eing Jeng; Jung-Fa Tsai; Lee-Yea Chuang; Mei-Shang Ho; Zu-Yau Lin; Min-Yuh Hsieh; Shin-Chern Chen; Wan-Lung Chuang; Liang-Yen Wang; Ming-Lung Yu; Chia-Yen Dai; Jan-Gowth Chang
Journal:  Neoplasia       Date:  2007-11       Impact factor: 5.715

Review 9.  Using high-throughput genomics to study hepatitis C: what determines the outcome of infection?

Authors:  Kathie-Anne Walters; Michael G Katze
Journal:  Antiviral Res       Date:  2009-01-07       Impact factor: 5.970

Review 10.  Microarray-based analysis for hepatocellular carcinoma: from gene expression profiling to new challenges.

Authors:  Yutaka Midorikawa; Masatoshi Makuuchi; Wei Tang; Hiroyuki Aburatani
Journal:  World J Gastroenterol       Date:  2007-03-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.